Scientific Advisory Board

Prof. Lindmark (MD, PhD) is a world-renowned expert with a proven track record in drug development and discovery. An industry leader with wide therapeutic area expertise (Oncology, Respiratory, Inflammation, Dermatology, GI, Neurology). Throughout his long career at Astra Zeneca, he has held key positions including Global VP Development in Respiratory and Inflammation, and later on, he led the R&D at Almirall and clinical development at eTheRNA and Aslan. Prof. Lindmark also serves as a Scientific Advisor at various companies.

Prof. Shalit is an expert in infectious diseases, actively involved in various national committees of the Israeli Ministry of Health. He was awarded Certificate of Appreciation Declaration by the World Health Organization for his role in eradicating poliomyelitis in Israel. In the past, Prof. Shalit also served as the Director General of Schneider Children’s Hospital and of Carmel Hospital, and was the Chairman of the Israeli Society for Infectious Diseases. Prof. Shalit serves as a Member of the Scientific Advisory Board at BioLineRx, Ltd., NasVax, and Therapix Biosciences Ltd. Prof. Shalit served as a Member of the Scientific Advisory Board at Teva Innovative Ventures until 2011. Currently, he serves as CEO of the Galilee Biomedical Research Administration. Prof. Shalit holds an MD from Tel Aviv University and an MPA from Harvard University.

Dr. Stark is VP Global Clinical Development at Teva Pharmaceutical Industries, Ltd. Dr Stark is pioneer and expert in global clinical development strategy. Dr. Stark joined Teva in 1987, where she established, grown and developed the clinical department of the Innovative R&D Division of Teva and was responsible for the clinical development of Copaxone® and Azilect®. During her long term career in the industry, Dr Stark was involved in building up new clinical therapeutic areas such as Oncology and Biosimilars as well as advancing new technologies into clinical trials. Dr. Stark holds a Ph.D. in Pathology from the Sackler School of Medicine, Tel Aviv University, and a Post-Doctorate in Immuno-Histopathology from Tel Aviv University and the Weizmann Institute of Science.

Dr. Noonan is the CEO of Lightstone Singapore PTE. Ltd. Previously Dr.Noonan was a senior partner and head of the European Life Sciences practice at L.E.K. Consulting LLP. He has been a BOD member of public and private life science companies in both the U.S. and Europe to include Intercept Pharmaceuticals Inc., Kailos Genetics and Orchid Biosciences. Dr. Noonan holds a Ph.D in Biochemistry from Princeton University.